Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Noah Federman, Catherine Michelle Albert, Brian Turpin, Leo Mascarenhas, Ramamoorthy Nagasubramanian, Birgit Geoerger, Michela Casanova, Maria Soledad Gallego Melcon, Julia Chisholm, Cornelis M. Van Tilburg, Neerav Narendra Shukla, Sheri L. Spunt, Michael Craig Cox, Douglas S. Hawkins, Alberto S. Pappo, Stefan S. Bielack, Francois P. Doz, Gianni Bisogno, Theodore Willis Laetsch, Steven G. DuBois, Larotrectinib SCOUT Investigators
Institutions: University of California, Los Angeles, Johns Hopkins University, Johns Hopkins Hospital, Cincinnati Children's Hospital Medical Center, University of Southern California, Children's Hospital of Los Angeles, Nemours Children's Clinic, Institut Gustave Roussy, Fondazione IRCCS Istituto Nazionale dei Tumori, Vall d'Hebron Hospital Universitari, Royal Marsden NHS Foundation Trust, National Center for Tumor Diseases, Hopp Children's Cancer Center Heidelberg, Memorial Sloan Kettering Cancer Center, Stanford Medicine, Stanford University, Seattle Children's Hospital, University of Washington, Fred Hutch Cancer Center, St. Jude Children's Research Hospital, Olgahospital, Klinikum Stuttgart, Institut Curie, University of Padua, The University of Texas Southwestern Medical Center, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889904595